uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
November 17, 2022 07:05 ET
|
uniQure Inc.
~ Event to be Webcast Live on uniQure’s Corporate Website at 8:30 a.m. EST ~ LEXINGTON, Ma. and AMSTERDAM, Nov. 17, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy...
Cyclacel Hosting Research & Development Day
October 24, 2022 09:15 ET
|
Cyclacel
-Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CYC140, for the Treatment of Advanced Solid Tumors and Lymphoma- -Monday, October 31st @ 10 am ET- ...
Praxis Precision Medicines to Host Epilepsy Day on April 27, 2022
April 13, 2022 08:00 ET
|
Praxis Precision Medicines, Inc.
BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Silence Therapeutics to Host R&D Day on October 21, 2021
October 07, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics to Host R&D Day on October 21, 2021 7 October 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery,...
Travere Therapeutics to Host Virtual R&D Day on Wednesday, December 9, 2020
December 01, 2020 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that the Company will host a virtual R&D Day on Wednesday, December 9, 2020 at 12:00 p.m. ET to...
Surface Oncology Announces Filing of IND for CD39 Targeted Antibody Candidate, SRF617, at Inaugural R&D Day
November 18, 2019 06:30 ET
|
Surface Oncology, Inc.
Details clinical plans for phase 1/1b clinical studies of SRF617 and SRF388 in patients with advanced solid tumors Shares preclinical data for new, CD112R targeted antibody candidate, SRF813, and its...
Autolus Therapeutics Unveils Expanded Next Generation Technology and Pipeline and Provides Key Update on AUTO3 Program in Pediatric ALL at R&D Day
March 26, 2019 06:00 ET
|
Autolus Therapeutics plc
LONDON, March 26, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next generation programmed T cell therapies for the...
ObsEva R&D Day Showcases Multiple Women’s Health Programs and Outlines Plans for Transition to Commercial Operations
December 07, 2018 12:12 ET
|
ObsEva SA
Clinical Trial Data and Regulatory Progress on Lead Programs Targeting IVF, Endometriosis, and Uterine Fibroids to Transform Company in 2019 GENEVA, Switzerland and BOSTON, Mass. (December...
ObsEva SA to Host R&D Investor Day December 7, 2018
November 29, 2018 01:30 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – November 29, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics...